Screener
Iovance Biotherapeutics, Inc. IOVA Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Proceeds from the issuance of common stock, net | 148,081 | 162,009 |
| Net cash provided by financing activities | 143,623 | 156,545 |
| Effect of foreign exchange rate changes | (337) | 1,247 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (52,285) | 16,360 |
| Cash, Cash Equivalents and Restricted Cash Beginning of Period | 169,058 | 122,053 |
| Cash, Cash Equivalents and Restricted Cash End of Period | $116,773 | $138,413 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Net unrealized loss on investments | 137 | 140 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s net change in cash?
- Iovance Biotherapeutics, Inc. (IOVA) reported net change in cash of -$85.73M in Q2 2026.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s net change in cash?
- Over 2 years (2022 to 2024), Iovance Biotherapeutics, Inc.'s net change in cash has grown at a -37.9% compound annual growth rate (CAGR), from $153.85M to -$59.27M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Iovance Biotherapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude